Recombinant factor IX (BeneFix) by adjusted continuous infusion: a study of stability, sterility and clinical experience. 2001

P Chowdary, and H Dasani, and J A Jones, and C M Loran, and A Eldridge, and S Hughes, and P W Collins
Arthur Bloom Centre for Haemophilia, Department of Haematology, University Hospital of Wales, Cardiff, UK.

The safety and efficacy of adjusted continuous infusion (CI) of recombinant factor IX (FIX; BeneFix) was assessed in vitro and in a clinical study. BeneFix was reconstituted at 100 IU mL-1 with or without unfractionated heparin (4 U mL-1) and stored at either 4 degrees C or room temperature. Reconstituted BeneFix retained at least 90% activity over 14 days if stored at 4 degrees C but stability was reduced at room temperature. BeneFix reconstituted in a sterile pharmacy was free of bacterial contamination. Six patients with haemophilia B received seven CIs of BeneFix to cover routine surgery and severe bleeding episodes. The CIs lasted between 3 and 10 days. In all cases, haemostasis was excellent and the desired therapeutic FIX level was easily maintained. No thrombotic episodes or inhibitor development occurred but two patients developed thrombophlebitis at the infusion site when heparin was not added to the infusion. BeneFix is not currently licensed for CI and we suggest that studies to enable licensing should be established as soon as possible.

UI MeSH Term Description Entries
D007231 Infant, Newborn An infant during the first 28 days after birth. Neonate,Newborns,Infants, Newborn,Neonates,Newborn,Newborn Infant,Newborn Infants
D007260 Infusion Pumps Fluid propulsion systems driven mechanically, electrically, or osmotically that are used to inject (or infuse) over time agents into a patient or experimental animal; used routinely in hospitals to maintain a patent intravenous line, to administer antineoplastic agents and other drugs in thromboembolism, heart disease, diabetes mellitus (INSULIN INFUSION SYSTEMS is also available), and other disorders. Drug Infusion Systems,Infusion Pump,Infusion Pumps, External,Infusors,Intravenous Drug Delivery System,Intravenous Drug Delivery Systems,Perfusion Pumps,Pumps, Infusion,Drug Infusion System,External Infusion Pump,External Infusion Pumps,Infusion Pump, External,Infusion System, Drug,Infusion Systems, Drug,Infusor,Perfusion Pump,Pump, External Infusion,Pump, Infusion,Pump, Perfusion,Pumps, External Infusion,Pumps, Perfusion,System, Drug Infusion,Systems, Drug Infusion
D008297 Male Males
D008657 Metabolic Clearance Rate Volume of biological fluid completely cleared of drug metabolites as measured in unit time. Elimination occurs as a result of metabolic processes in the kidney, liver, saliva, sweat, intestine, heart, brain, or other site. Total Body Clearance Rate,Clearance Rate, Metabolic,Clearance Rates, Metabolic,Metabolic Clearance Rates,Rate, Metabolic Clearance,Rates, Metabolic Clearance
D011994 Recombinant Proteins Proteins prepared by recombinant DNA technology. Biosynthetic Protein,Biosynthetic Proteins,DNA Recombinant Proteins,Recombinant Protein,Proteins, Biosynthetic,Proteins, Recombinant DNA,DNA Proteins, Recombinant,Protein, Biosynthetic,Protein, Recombinant,Proteins, DNA Recombinant,Proteins, Recombinant,Recombinant DNA Proteins,Recombinant Proteins, DNA
D002836 Hemophilia B A deficiency of blood coagulation factor IX inherited as an X-linked disorder. (Also known as Christmas Disease, after the first patient studied in detail, not the holy day.) Historical and clinical features resemble those in classic hemophilia (HEMOPHILIA A), but patients present with fewer symptoms. Severity of bleeding is usually similar in members of a single family. Many patients are asymptomatic until the hemostatic system is stressed by surgery or trauma. Treatment is similar to that for hemophilia A. (From Cecil Textbook of Medicine, 19th ed, p1008) Christmas Disease,Factor IX Deficiency,Deficiency, Factor IX,F9 Deficiency,Haemophilia B,Hemophilia B Leyden,Hemophilia B(M),Plasma Thromboplastin Component Deficiency,Bs, Hemophilia,Deficiencies, F9,Deficiencies, Factor IX,Deficiency, F9,Disease, Christmas,F9 Deficiencies,Factor IX Deficiencies,Haemophilia Bs,Hemophilia Bs,Hemophilia Bs (M)
D003257 Consumer Product Safety The sum total of measures taken and regulatory policies enacted to ensure the safe use of consumer products. Safety, Consumer Product,Product Approval,Product Approvals,Product Safety, Consumer
D004341 Drug Evaluation Any process by which toxicity, metabolism, absorption, elimination, preferred route of administration, safe dosage range, etc., for a drug or group of drugs is determined through clinical assessment in humans or veterinary animals. Evaluation Studies, Drug,Drug Evaluation Studies,Drug Evaluation Study,Drug Evaluations,Evaluation Study, Drug,Evaluation, Drug,Evaluations, Drug,Studies, Drug Evaluation,Study, Drug Evaluation
D004355 Drug Stability The chemical and physical integrity of a pharmaceutical product. Drug Shelf Life,Drugs Shelf Lives,Shelf Life, Drugs,Drug Stabilities,Drugs Shelf Life,Drugs Shelf Live,Life, Drugs Shelf,Shelf Life, Drug,Shelf Live, Drugs,Shelf Lives, Drugs
D005164 Factor IX Storage-stable blood coagulation factor acting in the intrinsic pathway of blood coagulation. Its activated form, IXa, forms a complex with factor VIII and calcium on platelet factor 3 to activate factor X to Xa. Deficiency of factor IX results in HEMOPHILIA B (Christmas Disease). Autoprothrombin II,Christmas Factor,Coagulation Factor IX,Plasma Thromboplastin Component,Blood Coagulation Factor IX,Factor 9,Factor IX Complex,Factor IX Fraction,Factor Nine,Factor IX, Coagulation

Related Publications

P Chowdary, and H Dasani, and J A Jones, and C M Loran, and A Eldridge, and S Hughes, and P W Collins
September 1999, American journal of hematology,
P Chowdary, and H Dasani, and J A Jones, and C M Loran, and A Eldridge, and S Hughes, and P W Collins
September 2015, Haemophilia : the official journal of the World Federation of Hemophilia,
P Chowdary, and H Dasani, and J A Jones, and C M Loran, and A Eldridge, and S Hughes, and P W Collins
January 2002, Developments in biologicals,
P Chowdary, and H Dasani, and J A Jones, and C M Loran, and A Eldridge, and S Hughes, and P W Collins
January 2002, Haemophilia : the official journal of the World Federation of Hemophilia,
P Chowdary, and H Dasani, and J A Jones, and C M Loran, and A Eldridge, and S Hughes, and P W Collins
March 1998, Blood coagulation & fibrinolysis : an international journal in haemostasis and thrombosis,
P Chowdary, and H Dasani, and J A Jones, and C M Loran, and A Eldridge, and S Hughes, and P W Collins
March 2001, Thrombosis and haemostasis,
P Chowdary, and H Dasani, and J A Jones, and C M Loran, and A Eldridge, and S Hughes, and P W Collins
November 1998, Haemophilia : the official journal of the World Federation of Hemophilia,
P Chowdary, and H Dasani, and J A Jones, and C M Loran, and A Eldridge, and S Hughes, and P W Collins
October 2020, TH open : companion journal to thrombosis and haemostasis,
P Chowdary, and H Dasani, and J A Jones, and C M Loran, and A Eldridge, and S Hughes, and P W Collins
September 2008, Blood transfusion = Trasfusione del sangue,
P Chowdary, and H Dasani, and J A Jones, and C M Loran, and A Eldridge, and S Hughes, and P W Collins
September 2010, Australian dental journal,
Copied contents to your clipboard!